Table 1.
Clinicopathologic features of published cases with de novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements
| Case (ref. n) | Age/sex | Extramedullary lesion at presentation | CNS | FAB criteria | Immunophenotype | Main cytogenetic abnormalities | FISH or gene analysis | Curative therapy | Survival | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CD10 | CD19 | CD20 | sIg | IGH-BCL2 | MYC | ||||||||
| 1 (8) | 57/F | bone | + | L3 | + | + | – | ND | t(8;22)(q24;q12a),t(14;18)(q32;q21) | NA | NA | ALL regimen | 7 mo |
| 2 (9) | 74/M | palate, L (cervical, pretracheal) | – | L3 | NA | + | NA | μ | t(8;22)(q24;q11),t(14;18)(q32;q21) | NA | NA | ALL regimen | 3 mo |
| 3 (9) | 37/M | none | – | L2 | – | + | + | IgMλ | t(8;22)(q24;q11),t(14;18)(q32;q21) | NA | NA | ALL regimen | 12 mo |
| 4 (9) | 73/M | none | + | L3 | + | + | + | IgMκ | t(8;22)(q24;q11),t(14;18)(q32;q21) | NA | NA | ALL regimen | 8 mo |
| 5 (10) | 62/M | H, S | – | L3 | + | + | + | ND | t(8;14)(q24;q32),t(14;18)(q32;q21) | NA | NA | ALL regimen | 3 mo |
| 6 (11) | 35/M | none | – | L3 | + | + | NA | ND | t(14;18)(q32;q21) | GR (+) | GR (+) | ALL regimen | 0.3 mo |
| 7 (12) | 27/M | L (IP, RP) | + | L3 | + | + | – | ND | t(8;22)(q24;q11),der(14)t(14;18)(q32;q21) | NA | NA | ALL regimen | 5 mo |
| 8 (13) | 67/M | none | – | L3 | NA | + | + | IgGκ | t(8;22)(q24;q11),t(14;18)(q32;q21) | NA | NA | none | 0.1 mo |
| 9 (14) | 71/M | none | – | L3 | −/+ | + | + | IgMλ | t(1;3;11)(q42.3;q27.1;q23.1),der(8)t(8;9)(q24.2;p13.3),t(14;18)(q32.3;q21.3),der(17)t(17;?)(p13;?) | GR (+) | GR (+) | none | 0.1 mo |
| 10 (15) | 36/F | IP mass | – | NA | + | + | NA | ND | t(8;22)(q24;q11),t(14;18)(q32;q21) | NA | GR (−) | ALL regimen | 3 mo |
| 11 (15) | 60 M | none | + | L2 | NA | NA | NA | NA | t(8;22)(q24;q11),t(14;18)(q32;q21),+der(14)t(14;18)(q32;q21) | NA | GR (−) | ALL regimen | 6 mo |
| 12 (16) | 40/M | GL, paravertebral mass | – | L2 | + | + | + | NA | der(6)t(6;8)(q1?;q24),add(8)(q24),der(9)t(8;9)(q24;p1?),t(14;18)(q32;q21),del(17)(p11) | NA | NA | ALL regimen | 1 mo |
| 13 (17) | 69/M | H | – | L3 | – | + | + | IgMκ | der(7;17)(q10;q10),+der(8)t(8;14;18)(q24;q32;q22),add(14)(q32),del(18)(q21) | GR (+) | NA | ALL regimen | 5 mo |
| 14 (18) | 41/F | none | – | L3 | + | + | + | NA | t(2;3)(p12;q27),del(8)(q24),t(14;18)(q32;q21) | GR (+) | GR (+) | ALL regimen | 10 mo |
| 15 (19) | 50/F | GL | – | L2 | + | + | + | IgMκ | t(3;4)(q27;p13),t(8;14;18)(q24;q32;q21),+ider(8)(q10)t(8;14;18)(q24;q32;q21) | GR (+) | GR (+) | ALL regimen | 0.1 mo |
| 16 (19) | 44/M | GL, S | + | NA | + | + | + | IgMκ | t(3;13)(q27;q14),t(8;22)(q24;q11),t(14;18)(q32;q21),+der(18)t(14;18)(q32;q21) | GR (+) | GR (−) | NCVBP, IVAM, ASCT | 7 mo |
| 17 (19) | 46/F | GL, S, Asc, PE | + | L2 | + | + | + | IgMκ | t(2;3)(p12;q27),add(8)(q24),der(14)t(8;14)(q24;q32),der(18)t(14;18)(q32;q21) | GR (+) | GR (+) | ACVBP, allo-SCT | 3 mo |
| 18 (20) | 62/F | none | NA | L3 | NA | NA | NA | NA | t(2;8)(p12;q24),t(14;18)(q32;q21) | NA | NA | none | 0.1 mo |
| 19 (21) | 48/M | GL | – | L2 | NA | NA | NA | NA | t(8;9)(q24,p13),t(14;18)(q32;q21) | NA | NA | R-CHOP | 3.5 mo |
| 20 (22) | 72/M | H, S | – | L2 | + | NA | + | IgGκ | t(8;9)(q24;p13),t(14;18)(q32;q21) | NA | NA | R-EPOCH | 4 mo |
| 21 (23) | 71/M | S (mild) | – | L2 | – | + | + | γ | t(1;2)(q22–23;p13),t(8;14)(q24;q32),t(14;18)(q32;q22) | GR (+) | GR (+) | ALL regimen | 2 mo |
| 22 (24) | 50/F | L (axillary), SC mass | – | L3 | + | + | NA | ND | t(2;3)(p12;q27),t(8;22)(q24;q11),t(14;18)(q32;q21),-17 | fusion (+) | split (+) | ALL regimen | 7 mo |
| 23 (25) | 29/M | none | – | L3 | + | + | + | NA | +8,t(8;22)(q24;q11),t(14;18)(q32;q21) | NA | split (+) | R-CHOP, R-ICE, R-hyper-CVAD/MA | 5 mo |
| 24 (25) | 72/M | none | – | L3 | + | + | + | NA | t(8;22)(q24;q11.2),t(14;18)(q32;q21) | NA | NA | R-hyper-CVAD/MA | 11 mob |
| 25 (25) | 50/F | none | + | L3 | + | + | + | NA | t(8;22)(q24;q11),t(14;18)(q32;q21) | fusion (+) | split (+) | R-hyper-CVAD/MA | 3 mo |
| 26 (25) | 32/M | L (mesenteric) | + | L3 | + | + | + | NA | t(1;3)(p32;q26.2),t(8;22)(q24;q11),add(14)(q32),t(14;18)(q32;q21) | fusion (+) | split (+) | hyper-CVAD/MA | 8 mo |
| 27 (25) | 67/M | L (P), small intestine | + | L3 | + | + | + | NA | t(8;14)(q24;q32),der(8)t(8;14)t(14;18)(q32;q21),der(14)t(8;14),+add(14)(q32),i(17)(q10) | fusion (+) | split (+) | R-hyper-CVAD/MA, velcade | 9 mo |
| 28 (25) | 61/M | L (RP), colon, prostate | + | L3 | NA | NA | NA | NA | t(8;22)(q24;q11),t(14;18)(q32;q21),+der(14)t(14;18) | fusion (+) | NA | hyper-CVAD/MA, MOAP | 9 mo |
| 29 (25) | 42/F | small intestine, omentum, breast | – | L3 | + | + | + | NA | t(8;14)(q24;q32),t(14;18)(q32;q21),der(17)t(10;17)(q22;q10) | fusion (+) | NA | proMACECytaBOM, CHOP, ESHAP, hyper-CVAD/MA, SCT, RT | 12 mo |
| 30 (25) | 63/M | testis, lip | – | L3 | + | + | + | NA | NA | fusion (+) | split (+) | hyper-CVAD | 18 mo |
| 31 (26) | 57/F | none | NA | NA | + | + | – | NA | der(3)t(3;14;?)(q27;q32;?),t(8;14)(q24;q32),der(18)t(14;18)(q32;q21) | fusion (+) | split (+) | CODOX-M/IVAC | 2.5 mo |
| 32 (26) | 60/M | none | NA | L3 | + | + | + | D | t(2;8)(p12;q24),der(8)t(2;8)(p12;q24),t(14;18)(q32;q21),?i(17)(q10) | fusion (+) | split (+) | hyper-CVAD, CODOX-M | 3 mo |
| 33 (26) | 63/M | GL, S (mild) | NA | L3 | + | + | + | D | der(3)t(1;3)(q23;q27),t(8;22)(q24;q11),t(14;18)(q32;q21) | fusion (+) | split (+) | CODOX-M/IVAC | 6 mo |
| 34 (26) | 76/F | none | NA | L3 | – | + | NA | D | t(8;22)(q24,q11),t(14;18)(q32;q21) | fusion (+) | split (+) | VAD | 6 mo |
| 35 (26) | 59/F | none | NA | L2 | + | NA | NA | NA | t(8;9)(q24;p13),t(14;18)(q32;q21) | fusion (+) | split (+) | ALL regimen | 1.5 mo |
| 36 (26) | 69/M | L (IP), H | NA | L3 | + | + | + | D | t(14;18)(q32;q21) | fusion (+) | split (+) | ALL regimen | 1.5 mo |
| 37 (26) | 86/F | none | NA | L2 | + | + | + | ND | add(9)(p13),t(14;18)(q32;q21) | fusion (+) | split (+) | none | 0.5 mo |
| 38 (27) | 43/F | pancreas | + | L3 | + | + | + | IgMλ | t(8;14)(q24;q32),t(14;18)(q32;q21) | fusion (+) | split (+) | R-CODOX-M/IVAC | 5 mo |
| 39 (28) | 61/M | GL, S, PE | – | L3 | + | + | + | γ | t(3;5)(q27;q15),t(8;14;18)(q24;q32;q21),+der(8)t(8;14;18),+der(18)t(8;14;18) | fusion (+) | split (+) | R-hyper-CVAD, | NAc |
| 40 (29) | 42/M | L (IP), S | + | L2 | + | + | + | κ | der(8)del(8)(q12.1q12.3)del(8)(q24.21q24.21)t(8;12)(q24.21;p12.1),der(12)del(12)(p12.1p12.1)t(8;12)(q24.21;p12.1),t(14;18)(q32;q21) | fusion (+) | split (+) | R-CHOP, ALL regimen | 7 mo |
| 41 (30) | 72/M | bone, liver | + | NA | + | NA | + | NA | t(3;8)(q27;q24),t(14;18)(q32;q21) | fusion (+) | split (+) | ALL regimen | NAc |
| 42 (31) | 64/M | L (NA) | – | NA | + | NA | + | NA | NA | fusion (+) | split (+) | R-EPOCH | 1.7 moc |
| 43 (31) | 72/M | L (NA) | – | NA | + | NA | + | NA | t(3;22)(q27;q11.2),t(8;14)(q24;q32),t(14;18)(q32;q21) | fusion (+) | split (+) | R-EPOCH | 1.6 moc |
| 44 (32) | 74/F | none | + | L2 | + | + | + | κ | –8,del(11)(q23q25),del(13)(q12q14),t(14;18)(q32;q21),+18 | fusion (+) | split (+) | R-CHOP | 3 mo |
| 45 (32) | 67/M | colon | – | L3 | + | + | −/+ | κ | NA | fusion (+) | split (+) | R-CHOP | 11 mod |
| 46 (32) | 71/M | L (mediastinal) | – | L3 | + | + | + | κ | der(8)t(8;14;18)(q24;q32;q21),der(14)t(8;14)(q24.1;q32),der(18)t(14;18)(q32;q21) | fusion (+) | split (+) | R-EPOCH, R-ICE, ASCT | 14 mo |
| 47 (33) | 60/M | GL | NA | L2 | + | + | + | λ | +8,inv(8)(p11.2q24)×2,t(14;18)(q32;q21),-17 | fusion (+) | split (+) | R-hyperCVAD, ofatumumab + EPOCH | 18 mo |
| 48 (present case) | 69/F | none | – | L2 | + | + | + | IgMκ | add(8)(q24),t(14;18)(q32;q21),-17 | fusion (+) | split (+), EC (+) | R-hyper-CVAD/MA, R-EPOCH | 7 mo |
Abbreviations: Ref n reference number, FAB criteria blastoid cell morphology according to the French-American-British classification, CNS development of central nervous system involvement, sIg surface immunoglobulin, M male, F female, L lymphadenopathy, H hepatomegaly, S splenomegaly, SC subcutaneous, IP intraperitoneal, RP retroperitoneal, GL generalized lymphadenopathy, Asc ascites, PE pleural effusion, P pelvic, ND not detected, D detected, NA not available, GR gene rearrangement, EC extra copies, ALL regimen multidrug chemotherapy for acute lymphoblastic leukemia, NCVBP mitoxantrone, cyclophosphamide, vinblastine, bleomycin, and prednisone, IVAM ifosfamide, etoposide, cytarabine, and methotrexate, ASCT autologous stem cell transplantation, ACVBP doxorubicin, cyclophosphamide, vinblastine, bleomycin, and prednisone, allo-SCT allogeneic stem cell transplantation, R rituximab, CHOP cyclophosphamide, doxorubicin, vincristine, and prednisone, EPOCH etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin, ICE ifosfamide, carboplatin, and etoposide, hyper-CVAD/MA cyclophosphamide, vincristine, doxorubicin, dexamethasone alternating with methotrexate and cytarabine, MOAP methotrexate, vincristine, asparaginase, and prednisone, proMACEcytaBOM prednisone, vincristine, methotrexate, doxorubicin, cyclophosphamide, etoposide, cytarabine, and bleomycin, ESHAP etoposide, methylprednisolone, cytarabine, and cisplatin, RT radiation therapy, CODOX-M/IVAC cyclophosphamide, vincristine, doxorubicin, methotrexate alternating with ifosfamide, etoposide, and cytarabine, VAD vincristine, doxorubicin, and dexamethasone, POMP prednisone, vincristine, methotrexate, and mercaptopurine
aThis description is according to original work [8]
bAlive (disease status was not described)
cAlive with disease at the time of publication
dAlive with no evidence of disease at the time of publication